Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 9Breast Neoplasms 8Triple Negative Breast Neoplasms 7Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Osteosarcoma 2Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Pathologic Complete Response 1Neutropenia 1Neoplasms 1NSCLC 1Myelosuppression 1Limited Stage Small Cell Lung Cancer 1Hemangiosarcoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Advanced Squamous Non-Small-Cell Lung Cancer 1

Interventions

trilaciclib 1tislelizumab 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Squamous Non-Small-Cell Lung Cancer × trilaciclib × Clear all
NCT05900921 2023-06-13

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Sichuan University

Phase 2 Unknown
132 enrolled
Thoracic

Advanced Squamous Non-Small-Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡